Fig. 3From: The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patientsELN risk score. OS (a), but not EFS (b), was significantly conditioned by the ELN risk score, with 57% of patients living at 12 months in the subgroup of those at “favorable” risk versus 40% of those at “intermediate/adverse risk” (p = 0.04)Back to article page